Brett Garabedian

Title: Brett Garabedian: Inventor in T-Cell Immunotherapy

Introduction

Brett Garabedian is an inventor associated with Scripps Research Institute and based in Del Mar, California. His patent work concerns methods intended to enhance T-cell activation and expansion, an area of research relevant to immune-based therapies.

Latest Patents

Garabedian is named on one patent: “Disruption of CD28-Sialoside Ligand Complexes to Enhance T Cell Activation.” The invention describes using a conjugate that combines a targeting component, which binds a molecule on T cells, with a sialidase enzyme or an active fragment of that enzyme. The proposed methods aim to enhance T-cell activation and expansion and stimulate an immune response. The patent also describes therapeutic conjugates, including combinations of sialidase with a T-cell-targeting antibody, such as an anti-PD-1 antibody. Garabedian’s listed portfolio includes 1 patent.

Career Highlights

Garabedian’s identified patent reflects research at the intersection of immunology and therapeutic development. The disclosed approach focuses on modifying interactions involving CD28 and sialoside ligands to support T-cell responses.

Collaborations

The patent lists James C. Paulson and Landon J. Edgar among Garabedian’s coworkers. Their shared work is associated with the research described in the patent.

Conclusion

Brett Garabedian’s patent contribution centers on an enzyme-targeting strategy designed to strengthen T-cell activation, highlighting the potential of collaborative research to inform immunotherapy development.